Free Trial

Equillium (EQ) Competitors

Equillium logo
$1.38 -0.08 (-5.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 +0.05 (+3.26%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EQ vs. LYEL, MREO, NMRA, ALEC, GALT, SCPH, TECX, ACB, JBIO, and IMMP

Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Lyell Immunopharma (LYEL), Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), Alector (ALEC), Galectin Therapeutics (GALT), scPharmaceuticals (SCPH), Tectonic Therapeutic (TECX), Aurora Cannabis (ACB), Jade Biosciences (JBIO), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry.

Equillium vs. Its Competitors

Equillium (NASDAQ:EQ) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

27.1% of Equillium shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 30.3% of Equillium shares are held by insiders. Comparatively, 22.3% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Equillium presently has a consensus target price of $1.00, suggesting a potential downside of 27.54%. Lyell Immunopharma has a consensus target price of $15.00, suggesting a potential downside of 13.39%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Equillium.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Equillium
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Lyell Immunopharma
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33

Equillium has higher revenue and earnings than Lyell Immunopharma. Equillium is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Equillium$41.10M2.00-$8.07M-$0.56-2.46
Lyell Immunopharma$60K5,545.58-$342.99M-$24.29-0.71

Equillium has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. Lyell Immunopharma's return on equity of -85.58% beat Equillium's return on equity.

Company Net Margins Return on Equity Return on Assets
EquilliumN/A -139.56% -90.56%
Lyell Immunopharma -552,328.31%-85.58%-68.85%

In the previous week, Equillium and Equillium both had 1 articles in the media. Equillium's average media sentiment score of -1.00 equaled Lyell Immunopharma'saverage media sentiment score.

Company Overall Sentiment
Equillium Negative
Lyell Immunopharma Negative

Equillium has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.

Summary

Equillium beats Lyell Immunopharma on 7 of the 13 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EQ vs. The Competition

MetricEquilliumMED IndustryMedical SectorNASDAQ Exchange
Market Cap$82.11M$3.44B$6.12B$10.63B
Dividend YieldN/A2.27%5.72%4.85%
P/E Ratio-2.4623.2229.2227.22
Price / Sales2.00271.03491.97186.54
Price / CashN/A45.2825.8230.35
Price / Book2.5610.6612.476.66
Net Income-$8.07M-$52.56M$3.31B$276.04M
7 Day Performance11.29%4.95%1.86%0.01%
1 Month Performance-5.48%16.47%8.42%3.60%
1 Year Performance23.21%14.84%63.51%32.71%

Equillium Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EQ
Equillium
0.4729 of 5 stars
$1.38
-5.5%
$1.00
-27.5%
+29.2%$82.11M$41.10M-2.4640Short Interest ↑
LYEL
Lyell Immunopharma
0.9213 of 5 stars
$16.83
+1.9%
$15.00
-10.9%
-22.9%$317.18M$60K-0.69270Positive News
Short Interest ↑
Gap Up
MREO
Mereo BioPharma Group
1.9805 of 5 stars
$2.00
+2.0%
$7.40
+270.0%
-51.5%$311.64M$10M-28.5740Gap Up
NMRA
Neumora Therapeutics
2.0031 of 5 stars
$1.86
-1.6%
$7.14
+284.0%
-89.0%$306.08MN/A-1.18108
ALEC
Alector
4.0652 of 5 stars
$3.04
+0.7%
$4.17
+37.1%
-33.7%$305.66M$100.56M-2.62270Positive News
Gap Down
Trading Halted
GALT
Galectin Therapeutics
1.2044 of 5 stars
$5.10
+8.1%
$6.00
+17.6%
+90.6%$302.36MN/A-7.979News Coverage
SCPH
scPharmaceuticals
3.7754 of 5 stars
$5.67
flat
$7.78
+37.3%
N/A$302.20M$49.97M-3.1330
TECX
Tectonic Therapeutic
2.3292 of 5 stars
$16.09
+0.4%
$80.29
+399.0%
-49.1%$299.77MN/A-3.98120News Coverage
Analyst Forecast
ACB
Aurora Cannabis
0.5412 of 5 stars
$5.40
+1.9%
N/A-4.7%$297.98M$246.72M-28.421,130
JBIO
Jade Biosciences
2.0074 of 5 stars
$9.09
+0.1%
$19.00
+109.0%
N/A$296.25MN/A-0.3020Gap Down
IMMP
Prima BioMed
0.7305 of 5 stars
$1.99
-1.0%
$7.00
+251.8%
+2.5%$295.86M$6.69M0.002,021News Coverage

Related Companies and Tools


This page (NASDAQ:EQ) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners